Safety of Anticoagulation Therapy in Cirrhotic Patients With PVT and Severe Thrombocytopenia

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
Severe thrombocytopenia (platelet count ≤ 50 × 10\^9/L) can significantly increase the risk of bleeding. Safety of Anticoagulation (AC) therapy in cirrhotic patients with portal vein thrombosis (PVT) and severe thrombocytopenia is unknown. Our study aimed to determine safety of AC therapy in cirrhotic PVT patients having platelet counts no less than 30×10\^9/L, especially in those with platelet counts between 30-50×10\^9/L.
Epistemonikos ID: b55e7f2d72522aa921fffa1d19c9c52ef451c436
First added on: Oct 22, 2026